BIOVIE INC. DL-,0001

Squarepoint Ops LLC purchased a new position in shares of BioVie Inc. (NASDAQ:BIVI – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,213 shares of the company’s stock, valued at approximately $28,000. Squarepoint Ops LLC owned about 0.08% of BioVie at the end of the most recent reporting period. Other institutional investors and hedge funds have also modified their holdings of the company. NewEdge Advisors LLC lifted its stake in shares of BioVie by 14,000.0% during the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock valued at $28,000 after buying an additional 14,000 shares in the last quarter. Northern Trust Corp purchased a new position in shares of BioVie during the 4th quarter valued at $34,000. Two Sigma Investments LP purchased a new position in shares of BioVie during the 4th quarter valued at $57,000. Prosperity Wealth Management Inc. purchased a new position in shares of BioVie during the 4th quarter valued at $63,000. Finally, Bank of Montreal Can purchased a new position in shares of BioVie during the 4th quarter valued at $100,000. Hedge funds and other institutional investors own 4.59% of the company’s stock. BioVie Price Performance Shares of BIVI stock opened at $1.10 on Wednesday. The company has a market capitalization of $20.43 million, a P/E ratio of -0.11 and a beta of 0.77. The company’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.55. BioVie Inc. has a one year low of $0.62 and a one year high of $7.50. BioVie (NASDAQ:BIVI – Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.17. Analyst Upgrades and Downgrades Separately, Brookline Capital Management upgraded shares of BioVie to a “strong-buy” rating in a report on Tuesday, March 18th. Check Out Our Latest Stock Analysis on BioVie About BioVie (Free Report) BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.» Mehr auf defenseworld.net

CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson's disease on Wednesday, May 28, 2025 at 12:00 PM ET. To register, click here.» Mehr auf globenewswire.com

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioVie Inc. (NASDAQ: BIVI) on behalf of long-term stockholders following a class action complaint that was filed against BioVie on January 19, 2024 with a Class Period from August 5, 2021 to November 29, 2023. Our investigation concerns whether the board of directors of BioVie have breached their fiduciary duties to the company.» Mehr auf globenewswire.com